Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748281 | 1.00 | IDO1 (0.56) | IDO1GAATHRBTDP1NPC1 | |
| SCHEMBL22410653 | 0.87 | IDO1 (0.53) | IDO1GAATHRBTDP1NPC1 | |
| SCHEMBL7461998 | 0.80 | LMNA (0.46) | TDP1MAPTCYP3A4ALDH1A1LMNA | |
| SCHEMBL6588863 | 0.80 | GPR35 (0.47) | GAATHRBNPC1RAB9AMAPT | |
| SCHEMBL6593057 | 0.80 | LMNA (0.46) | TDP1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL19142316 | 0.80 | MEN1 (0.46) | IDO1GAATHRBNPC1RAB9A | |
| SCHEMBL28961641 | 0.78 | LMNA (0.51) | GAATHRBNPC1RAB9ACYP3A4 | |
| SCHEMBL29571343 | 0.76 | LMNA (0.52) | TDP1NPC1RAB9ACYP3A4ALDH1A1 | |
| SCHEMBL6833141 | 0.76 | LMNA (0.52) | TDP1NPC1RAB9ACYP3A4ALDH1A1 | |
| SCHEMBL7463796 | 0.75 | MAPT (0.56) | NPC1RAB9AMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117418280-A | Nickel spraying plating solution, preparation method and electroplating method | 昆山一鼎工业科技有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-115976586-A | Positive and negative pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating | 昆山一鼎工业科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-117418280-A | Nickel spraying plating solution, preparation method and electroplating method | 昆山一鼎工业科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-115976586-A | Positive and negative pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating | 昆山一鼎工业科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-6642252-B2 | Anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in treating cancer. | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030166685-A1 | Acid derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| EP-1332131-A2 | ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-08-06 | — | — | EP | disclosed |
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002042273-A2 | ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166685-A1 | Acid derivatives useful as serine protease inhibitors | F9, F11, F12 | IDO1 3385/4885GAA 1681/4885THRB 3391/4885 |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | IDO1 3085/4885GAA 712/4885THRB 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.